Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models

Cancer Immunology Research

Volumn 4, Issue 1, 2016, Pages 49-60

  Rhode, Peter R ^a   Egan, Jack O ^a   Xu, Wenxin ^a   Hong, Hao ^b   Webb, Gabriela M ^c,d   Chen, Xiaoyue ^a   Liu, Bai ^a   Zhu, Xiaoyun ^a   Wen, Jinghai ^a   You, Lijing ^a   Kong, Lin ^a   Edwards, Ana C ^a   Han, Kaiping ^a   Shi, Sixiang ^b   Alter, Sarah ^a   Sacha, Jonah B ^c,d   Jeng, Emily K ^a   Cai, Weibo ^b   Wong, Hing C ^a  

^a ALTOR BIOSCIENCE CORPORATION   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALT 803; ANTINEOPLASTIC AGENT; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 15; UNCLASSIFIED DRUG; ALT-803; CYTOKINE; IMMUNOLOGICAL ADJUVANT; PROTEIN;

ALLOMETRY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; COLON CARCINOMA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MACACA FASCICULARIS; MELANOMA; MEMORY T LYMPHOCYTE; MONOCYTE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHARMACODYNAMICS; PLASMA HALF LIFE; POSITRON EMISSION TOMOGRAPHY; SPLEEN CELL; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CANCER TRANSPLANTATION; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; FEMALE; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; METABOLISM; PHYSIOLOGY; TISSUE DISTRIBUTION; TUMOR CELL LINE; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-15; KILLER CELLS, NATURAL; MACACA FASCICULARIS; MELANOMA, EXPERIMENTAL; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PROTEINS; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84960166465     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0093-T     Document Type: Article

References (46)

1. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. Highdose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
2. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10:6342S-6S.
3. Tarhini AA, Agarwala SS. Interleukin-2 for the treatment ofmelanoma. Curr Opin Investig Drugs 2005;6:1234-9.
4. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25 (hi) Foxp3+regulatory T cells in cancer patients. Blood 2006;107:2409-14.
5. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 formetastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169-77.
6. Sim GC, Martin-Orozco N, Jin L, Yang Y, Wu S, Washington E, et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014;124:99-110.
7. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008;222:357-68.
8. Sim GC, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev 2014;25:377-90.
9. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006;6:595-601.
10. Waldmann T, Tagaya Y, Bamford R. Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol 1998;16:205-26.
11. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002;17:537-47.
12. Sanjabi S, Mosaheb MM, Flavell RA. Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells. Immunity 2009;31:131-44.
13. Yoon SR, Kim TD, Choi I. Understanding of molecular mechanisms in natural killer cell therapy. Exp Mol Med 2015;47:e141.
14. Marcais A, Cherfils-Vicini J, Viant C, Degouve S, Viel S, Fenis A, et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol 2014;15:749-57.
15. Yang M, Li D, Chang Z, Yang Z, Tian Z, Dong Z. PDK1 orchestrates early NK cell development through induction of E4BP4 expression and maintenance of IL-15 responsiveness. J Exp Med 2015;212:253-65.
16. Munger W, DeJoy SQ, Jeyaseelan R Sr., Torley LW, Grabstein KH, Eisenmann J, et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 1995;165:289-93.
17. Waldmann TA, Lugli E, Roederer M, Perera LP, Smedley JV, Macallister RP, et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 2011;117:4787-95.
18. Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006;177:6072-80.
19. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, et al. Converting IL-15 to a superagonist by binding to soluble IL-15Ra. ProcNatl Acad Sci U S A 2006;103:9166-71.
20. Mortier E, Quemener A, Vusio P, Lorenzen I, Boublik Y, Grotzinger J, et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem 2006;281:1612-9.
21. Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol 2008;180:2099-106.
22. Zhu X, Marcus WD, Xu W, Lee HI, Han K, Egan JO, et al. Novel human interleukin-15 agonists. J Immunol 2009;183:3598-607.
23. Han KP, Zhu X, Liu B, Jeng E, Kong L, Yovandich JL, et al. IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 2011;56:804-10.
24. Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, et al. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 2008;68:2972-83.
25. Bessard A, Sole V, Bouchaud G, Quemener A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009;8:2736-45.
26. Ring AM, Lin JX, Feng D, Mitra S, Rickert M, Bowman GR, et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol 2012;13:1187-95.
27. Wu J. IL-15 agonists: the cancer cure cytokine. J Mol Genet Med 2013;7:85.
28. Mueller YM, Petrovas C, Bojczuk PM, Dimitriou ID, Beer B, Silvera P, et al. Interleukin-15 increases effector memory CD8+ T cells and NK Cells in simian immunodeficiency virus-infected macaques. J Virol 2005;79:4877-85.
29. Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC, et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009;114:2417-26.
30. Lugli E, Goldman CK, Perera LP, Smedley J, Pung R, Yovandich JL, et al. Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood 2010;116:3238-48.
31. Xu W, Jones M, Liu B, Zhu X, Johnson CB, Edwards AC, et al. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alpha Su/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res 2013;73:3075-86.
32. Rosario M, Liu B, Kong L, Collins L, Schneider SE, Chen X, et al. The IL-15-based ALT-803 complex enhances FcgammaRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas. Clin Cancer Res 2015 Sep. 30 [Epub ahead of print].
33. 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS One 2011;6:e28005.
34. Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging 2011;38:1335-43.
35. Stebbings R, Findlay L, Edwards C, Eastwood D, Bird C, North D, et al. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007;179:3325-31.
36. Wen J, Zhu X, Liu B, You L, Kong L, Lee HI, et al. Targeting activity of a TCR/IL-2 fusion protein against established tumors. Cancer Immunol Immunother 2008;57:1781-94.
37. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 2010;16:6019-28.
38. Kobayashi H, Carrasquillo JA, Paik CH, Waldmann TA, Tagaya Y. Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15. Cancer Res 2000;60:3577-83.
39. Eisenman J, Ahdieh M, Beers C, Brasel K, Kennedy MK, Le T, et al. Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine 2002;20:121-9.
40. Carson WE, Yu H, Dierksheide J, Pfeffer K, Bouchard P, Clark R, et al. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J Immunol 1999;162:4943-51.
41. Biber JL, Jabbour S, Parihar R, Dierksheide J, Hu Y, Baumann H, et al. Administration of two macrophage-derived interferon-gamma-inducing factors (IL-12 and IL-15) induces a lethal systemic inflammatory response in mice that is dependent on natural killer cells but does not require interferon-gamma. Cell Immunol 2002;216:31-42.
42. Sneller MC, Kopp WC, Engelke KJ, Yovandich JL, Creekmore SP, Waldmann TA, et al. IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. Blood 2011;118:6845-8.
43. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2015;33:74-82.
44. Romer PS, Berr S, Avota E, Na SY, Battaglia M, tenBerge I, et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 2011;118:6772-82.
45. Food and Drug Administration, HHS. Guidance for industry on estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Fed Regist 2005;70:42346.
46. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol 2013;43:2797-809.